Plus Therapeutics Inc.

08/12/2024 | Press release | Distributed by Public on 08/12/2024 05:42

Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference